Xtant Medical Finalizes Companion Spine Transactions

Rhea-AI Summary

Xtant Medical (NYSE American: XTNT) announced completion of its Companion Spine divestitures after receiving $10.7 million on March 2, 2026, bringing the total aggregate purchase price to $21.4 million for the Coflex assets and Paradigm OUS businesses.

Of the $10.7 million, $8.2 million satisfied an unsecured promissory note (plus accrued interest) and $2.2 million related to working capital and purchase price adjustments. Management said the proceeds will help reduce long-term debt and provide additional cash liquidity while refocusing the company on higher-margin biologics.

Positive

• Aggregate sale proceeds of $21.4 million finalized
• $10.7 million received March 2, 2026 closing remaining consideration
• $8.2 million satisfied Companion Spine promissory note plus interest
• Proceeds earmarked to reduce long-term debt and boost liquidity
• Divestitures allow sharper focus on higher-margin biologics

Negative

• None.

News Market Reaction – XTNT

+0.19%

1 alert

+0.19% News Effect

On the day this news was published, XTNT gained 0.19%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Final payment: $10.7 million Aggregate purchase price: $21.4 million Note repayment: $8.2 million +1 more

4 metrics

Final payment $10.7 million Received from Companion Spine to finalize divestiture transactions

Aggregate purchase price $21.4 million Total consideration for Coflex assets and Paradigm OUS businesses

Note repayment $8.2 million Satisfaction of unsecured promissory note plus accrued interest

Working capital adjustments $2.2 million Settlement of working capital and other purchase price adjustments

Market Reality Check

Price: $0.5714 Vol: Volume 75,333 is below th...

low vol

$0.5714 Last Close

Volume Volume 75,333 is below the 20-day average of 132,573, suggesting muted pre-news activity. low

Technical Shares at $0.5703 are trading below the 200-day MA of $0.67, indicating a weaker prevailing trend before this update.

Peers on Argus

Peers showed mixed moves: APYX -4.66%, LUNG -1.25%, alongside strong gains in T...

1 Up 1 Down

Peers showed mixed moves: APYX -4.66%, LUNG -1.25%, alongside strong gains in TELA +8.3% and BDMD +32.89%. With this dispersion and scanner data flagging both up and down movers, XTNT’s reaction appears more company-specific than sector-driven.

Historical Context

5 past events · Latest: Feb 25 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 25	Conference participation	Neutral	+0.8%	Management joining a musculoskeletal conference with webcast and investor meetings.
Dec 11	Product launch	Positive	-1.1%	Launch of next-generation nanOss Strata synthetic bone graft through U.S. network.
Dec 01	Divestiture completion	Positive	+1.8%	Companion Spine completing acquisition of Paradigm Spine and related implants.
Dec 01	Asset sale	Positive	+1.8%	Xtant closing sale of Coflex assets and Paradigm OUS businesses to Companion Spine.
Nov 10	Earnings report	Positive	-0.6%	Q3 2025 revenue growth, higher margins, positive net income and EBITDA.

Pattern Detected

Recent history shows mixed price reactions: some product and divestiture news drew positive moves, while strong earnings and a product launch saw mild sell-offs, indicating uneven follow-through on positive headlines.

Recent Company History

Over the last six months, Xtant has focused on portfolio reshaping and growth. It completed divestitures of Coflex and Paradigm OUS assets to Companion Spine on Dec 1, 2025, with stock gains around that time. Q3 2025 results on Nov 10 showed higher revenue and margins but a modest price dip. A new nanOss Strata bone graft launched on Dec 11, 2025 with a slight decline. Today’s final payment from Companion Spine continues this balance-sheet-focused divestiture theme.

Market Pulse Summary

This announcement finalizes the Companion Spine divestitures, converting an $8.2 million unsecured p...

Analysis

This announcement finalizes the Companion Spine divestitures, converting an $8.2 million unsecured promissory note and other adjustments into a $10.7 million cash inflow and confirming total consideration of $21.4 million. It continues Xtant’s strategy of focusing on higher-margin biologics while using proceeds to reduce long-term debt and bolster liquidity. Investors may watch subsequent balance-sheet updates, deployment of cash, and progress of the biologics portfolio to assess the long-term impact of these transactions.

Key Terms

unsecured promissory note, working capital, long-term debt, liquidity

4 terms

unsecured promissory note financial

"in satisfaction of the unsecured promissory note issued to Xtant by Companion Spine"

An unsecured promissory note is a written IOU in which a borrower promises to repay a loan plus any interest but does not pledge any asset as collateral. Investors care because it relies solely on the borrower’s ability to pay—like lending money to someone without holding their watch as security—so it usually carries higher interest and higher risk and ranks below secured debt if the borrower defaults, affecting expected recovery and company credit profile.

working capital financial

"an additional $2.2 million related to settlement of working capital and other purchase price"

Working capital is the money a business has available to cover its daily expenses, like paying bills and buying supplies. It’s like the cash in your wallet that helps you handle everyday costs; having enough ensures the business can operate smoothly without running into money shortages.

long-term debt financial

"these additional funds will allow us to further reduce long-term debt while providing"

Long-term debt is money a company has borrowed that it does not have to repay for more than one year, such as bank loans or bonds. It matters to investors because these obligations require future interest and principal payments that can reduce cash available for growth or dividends; like a household mortgage, manageable long-term debt can finance expansion, but too much increases the risk that the company will struggle to meet payments.

liquidity financial

"reduce long-term debt while providing additional cash liquidity"

Liquidity is how easily and quickly an asset or investment can be converted into cash without losing value. It matters to investors because higher liquidity means they can access their money quickly if needed, while lower liquidity can make it harder to sell assets promptly or at a fair price, potentially creating financial challenges. Think of it like trying to sell a common item versus a rare collectible—it's much easier to sell the common item fast.

AI-generated analysis. Not financial advice.

Xtant received $10.7 million in satisfaction of unsecured promissory note issued to Xtant by Companion Spine plus related working capital adjustments

BELGRADE, Mont., March 2, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it has received $10.7 million from Companion Spine related to Companion Spine's purchase of Xtant's Coflex® assets and Paradigm OUS businesses in December 2025, bringing the total aggregate purchase price for the two divestitures to $21.4 million. With this payment, the transactions have now been finalized.

Of the $10.7 million recently received by Xtant, $8.2 million was in satisfaction of the unsecured promissory note issued to Xtant by Companion Spine, plus accrued interest thereon, and an additional $2.2 million related to settlement of working capital and other purchase price adjustments.    

Sean Browne, President and CEO of Xtant Medical, stated, "We are very pleased to finalize these transactions with Companion Spine, which place these assets and businesses with a recognized leader in the neuro-musculoskeletal space while allowing us to further sharpen our focus on our higher-margin biologics business. We wish Companion Spine much success in achieving the full market potential of these motion preservation technologies."

"Importantly, these additional funds will allow us to further reduce long-term debt while providing additional cash liquidity," Mr. Browne concluded.

About Xtant Medical Holdings, Inc.

Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that contain words such as "intends," ''expects,'' ''anticipates,'' ''plans,'' ''believes,'' ''estimates,'' "continue," "future," ''will,'' "potential," similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company's expectations regarding the reduction of its long-term debt and increased liquidity. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's future operating and financial performance and its ability to increase or maintain revenue; and other risk factors  contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on March 6, 2025 and subsequent SEC filings by the Company, including without limitation its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 filed with the SEC on November 10, 2025. Investors are encouraged to read the Company's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/xtant-medical-finalizes-companion-spine-transactions-302700593.html

SOURCE Xtant Medical Holdings, Inc.

FAQ

What did Xtant (XTNT) receive from Companion Spine on March 2, 2026?

Xtant received $10.7 million on March 2, 2026 to finalize the divestitures. According to the company, $8.2 million satisfied an unsecured promissory note and $2.2 million settled working capital and purchase price adjustments.

How much was the total purchase price for Xtant's Coflex and Paradigm OUS businesses?

The total aggregate purchase price was $21.4 million for the two divestitures. According to the company, the March 2 payment completed the remaining consideration from Companion Spine.

How will the March 2, 2026 payment affect Xtant's balance sheet and debt?

The payment will help Xtant reduce long-term debt and increase cash liquidity. According to the company, the $10.7 million proceeds include debt satisfaction and purchase price adjustments that improve financial flexibility.

What assets did Xtant sell to Companion Spine in December 2025?

Xtant sold its Coflex® assets and Paradigm OUS businesses to Companion Spine in December 2025. According to the company, those divestitures were concluded with the March 2, 2026 payment, finalizing the transactions.

What strategic focus does Xtant plan after finalizing the Companion Spine transactions?

Xtant plans to sharpen its focus on its higher-margin biologics business following the divestitures. According to the company, moving these assets to Companion Spine allows Xtant to concentrate resources on biologics growth and profitability.